Preliminary research demonstrate that the compound – a dual agonist of GLP-1 and GIP receptors – may provide a substantial advance in body management therapies. In contrast to existing therapies, the peptide shows to modify hunger and energy expenditure by means of multiple routes. Despite additional examination is needed , current data raise e